- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01034631
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OUTLINE: This is a multi-center study.
Phase I: Patients will be accrued in the classic 3 patients per dose per cohort design, 21-day cycle
- Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2
- Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2
- Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2
- Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2
Phase II: Patients will be randomized 1:1 to Arm A or Arm B
Combination Arm A: Everolimus 10 mg + BNC105P MTD (from Phase 1 study) 21 day cycle
Sequential Arm B: Everolimus 10 mg 21 day cycle
- Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.
Karnofsky Performance Score (KPS) ≥70 within 7 days prior to registration for protocol therapy.
Life Expectancy: Not specified
Hematopoietic:
- White blood cell count (WBC) > 3.5 K/mm3
- Hemoglobin (Hgb) > 8.5 g/dL
- Platelets > 100 K/mm3
- Absolute neutrophil count (ANC) > 1.5 K/mm3
Hepatic:
- Total Bilirubin < 1.25 x ULN
- Aminotransferase (AST and ALT) < 2.5 x ULN
Renal:
- Serum Creatinine < 2.5 x ULN (upper limit normal)
Cardiovascular:
- No significant cardiovascular events within 6 months (CVA, CAD, peripheral arterial obstruction, arrhythmias, cardiac dysfunction) of registration for protocol therapy
- No history of clinical CHF or LVEF <50% by Echo (or MUGA) within 30 days prior to registration for protocol therapy.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Camperdown, New South Wales, Austrálie, 2050
- Royal Prince Alfred Hospital: Sydney Cancer Centre
-
Randwick, New South Wales, Austrálie, 2031
- Prince of Wales Hospital
-
Wahroonga, New South Wales, Austrálie, 2076
- Sydney Adventist Hospital Ltd.
-
-
Queensland
-
Greenslopes, Queensland, Austrálie, 4120
- Gallipoli Medical Research Foundation: Greenslopes Private Hospital
-
Herston, Queensland, Austrálie, 4029
- Royal Brisbane & Women's Hospital
-
Woolloongabba, Queensland, Austrálie, 4201
- Princess Alexandra Hospital
-
-
South Australia
-
Adelaide, South Australia, Austrálie, 5000
- Royal Adelaide Hospital
-
Kurralta Park, South Australia, Austrálie, 5037
- Ashford Cancer Centre
-
-
Tasmania
-
Launceston, Tasmania, Austrálie, 7250
- Gallipoli Medical Research Foundation: Launceston General Hospital
-
-
Victoria
-
Frankston, Victoria, Austrálie, 3199
- Peninsula Oncology Centre
-
Heidelberg, Victoria, Austrálie, 3084
- Austin Hospital
-
Melbourne, Victoria, Austrálie, 3004
- Alfred Hospital
-
-
Western Australia
-
Perth, Western Australia, Austrálie, 6000
- Royal Perth Hospital
-
-
-
-
-
Singapore, Singapur, 169610
- National Cancer Centre Singapore
-
-
-
-
Alabama
-
Muscle Shoals, Alabama, Spojené státy, 35661
- Northwest Alabama Cancer Center
-
-
Arkansas
-
Hot Springs, Arkansas, Spojené státy, 71913
- Genesis Cancer Center
-
-
California
-
Burbank, California, Spojené státy, 91505
- Providence Health System: Roy and Patricia Disney Family Cancer Center
-
Corona, California, Spojené státy, 92879
- Compassionate Cancer Care Medical Group, Inc.
-
Corona, California, Spojené státy, 92879
- Compassionate Cancer Care Medical Group
-
Duarte, California, Spojené státy, 91010
- City of Hope
-
Fountain Valley, California, Spojené státy, 92708
- Robert A. Moss, M.D., FACP, Inc.
-
Fresno, California, Spojené státy, 93720
- California Cancer Associates for Research and Excellence
-
Greenbrae, California, Spojené státy, 94904
- Marin Specialty Care
-
Los Angeles, California, Spojené státy, 90017
- Good Samaritan Hospital
-
Los Angeles, California, Spojené státy, 90095
- UCLA Med - Hematology & Oncology
-
Riverside, California, Spojené státy, 92501
- Compassionate Cancer Care Medical Group
-
Whittier, California, Spojené státy, 90603
- American Institute of Research
-
-
Colorado
-
Denver, Colorado, Spojené státy, 80210
- Centura Health Research Center
-
Golden, Colorado, Spojené státy, 80401
- Western Oncology & Hematology
-
-
Florida
-
Brooksville, Florida, Spojené státy, 34613
- Cancer Care Centers of Florida: Brooksville
-
Fort Lauderdale, Florida, Spojené státy, 33308
- Broward Oncology Associates
-
Gainesville, Florida, Spojené státy, 32610
- University of Florida, Shands Cancer Center
-
Jacksonville, Florida, Spojené státy, 32256
- Cancer Specialists of North Florida
-
Miami, Florida, Spojené státy, 33136
- Advanced Pharma CR, LLC
-
New Port Richey, Florida, Spojené státy, 34652
- Cancer Care Centers of Florida
-
Ocala, Florida, Spojené státy, 34471
- Ocala Cancer Institute
-
Rockledge, Florida, Spojené státy, 32955
- Cancer Care Centers of Brevard
-
-
Georgia
-
Athens, Georgia, Spojené státy, 30607
- Northeast Georgia Cancer Care, LLC
-
Dublin, Georgia, Spojené státy, 31021
- Dublin Hematology & Oncology Care
-
-
Idaho
-
Post Falls, Idaho, Spojené státy, 83854
- Kootenai Cancer Center
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center
-
Galesburg, Illinois, Spojené státy, 61401
- Medical & Surgical Specialists, LLC
-
Skokie, Illinois, Spojené státy, 60076
- Edward H. Kaplan, M.D., & Associates
-
-
Indiana
-
Evansville, Indiana, Spojené státy, 47713
- Deaconess Clinic
-
Fort Wayne, Indiana, Spojené státy, 46815
- Fort Wayne Oncology & Hematology, Inc
-
Goshen, Indiana, Spojené státy, 46527
- IU Health Goshen
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Spojené státy, 46219
- IU Health Central Indiana Cancer Centers
-
Indianapolis, Indiana, Spojené státy, 46256
- Community Regional Cancer Center
-
Lafayette, Indiana, Spojené státy, 47905
- Horizon Oncology Research
-
Muncie, Indiana, Spojené státy, 47303
- IU Health at Ball Memorial Hospital Cancer Center
-
Munster, Indiana, Spojené státy, 46321
- Monroe Medical Associates
-
Newburgh, Indiana, Spojené státy, 47630
- Oncology Hematology Associates of SW Indiana
-
South Bend, Indiana, Spojené státy, 46601
- Northern Indiana Cancer Research Consortium
-
-
Iowa
-
Sioux City, Iowa, Spojené státy, 51101
- Siouxland Hematology Oncology Associates, LLP, Nylen Cancer Center
-
-
Kansas
-
Wichita, Kansas, Spojené státy, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Hazard, Kentucky, Spojené státy, 41701
- Kentucky Cancer Clinic
-
Paducah, Kentucky, Spojené státy, 42001
- Purchase Cancer Group
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70809
- Medical Oncology LLC
-
Metairie, Louisiana, Spojené státy, 70006
- Metairie Oncologists
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- St. Joseph Mercy Hospital
-
Grand Rapids, Michigan, Spojené státy, 49546
- Cancer and Hematology Centers of Western Michigan
-
Wyoming, Michigan, Spojené státy, 49519
- Metro Health Cancer Care
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic
-
-
Montana
-
Bozeman, Montana, Spojené státy, 59715
- Bozeman Deaconness Cancer Center
-
Great Falls, Montana, Spojené státy, 59405
- Sletten Cancer Specialists
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68114
- Methodist Cancer Center
-
-
New Hampshire
-
Manchester, New Hampshire, Spojené státy, 03102
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Elizabeth, New Jersey, Spojené státy, 07202
- Trinitas Regional Medical Center
-
Somerville, New Jersey, Spojené státy, 08876
- Somerset Hematology Oncology Associates
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87110
- Presbyterian Medical Group
-
Albuquerque, New Mexico, Spojené státy, 87131
- University of New Mexico Cancer Center: Albuquerque
-
-
New York
-
Albany, New York, Spojené státy, 12208
- New York Oncology Hematology, PC
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Spojené státy, 11042
- NYU Langone Arena Oncology
-
New York, New York, Spojené státy, 10029
- Tisch Cancer Institute at Mount Sinai Medical Center
-
Nyack, New York, Spojené státy, 10960
- Hematology Oncology Associates of Rockland
-
-
North Carolina
-
Pinehurst, North Carolina, Spojené státy, 28374
- First Health of the Carolinas
-
-
Ohio
-
Middletown, Ohio, Spojené státy, 45042
- Signal Point Clinical Research Center
-
Wooster, Ohio, Spojené státy, 44691
- Lawrence M. Stallings, M.D.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73120
- Mercy Physicians Of Oklahoma
-
-
Oregon
-
Springfield, Oregon, Spojené státy, 97477
- Willamette Valley Cancer Institute
-
-
Pennsylvania
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Gettysburg, Pennsylvania, Spojené státy, 17235
- Gettysburg Cancer Center
-
Pittsburgh, Pennsylvania, Spojené státy, 15212
- Allegheny Cancer Center
-
State College, Pennsylvania, Spojené státy, 16803
- Mount Nittany Medical Center
-
West Reading, Pennsylvania, Spojené státy, 19611
- Berks Hematology Oncology Associates
-
-
Rhode Island
-
Cranston, Rhode Island, Spojené státy, 02920
- Hematology and Oncology Associates of Rhode Island
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- MUSC Hollings Cancer Center
-
Hilton Head Island, South Carolina, Spojené státy, 29926
- South Carolina Cancer Specialists
-
-
Tennessee
-
Germantown, Tennessee, Spojené státy, 38138
- The Jones Clinic, PC
-
-
Texas
-
Austin, Texas, Spojené státy, 78758
- Texas Oncology: Austin North
-
Bedford, Texas, Spojené státy, 76022
- Texas Oncology: Bedford
-
Dallas, Texas, Spojené státy, 75246
- Texas Oncology, PA
-
Fort Worth, Texas, Spojené státy, 76104
- Texas Oncology: Fort Worth
-
Houston, Texas, Spojené státy, 77030
- Methodist Hospital Research Institute
-
Houston, Texas, Spojené státy, 77024
- Texas Oncology: Houston Memorial City
-
Houston, Texas, Spojené státy, 77055
- Houston Cancer Center
-
Lubbock, Texas, Spojené státy, 79410
- Joe Arrington Cancer Research and Treatment Center
-
San Antonio, Texas, Spojené státy, 78229
- CTRC at The UT Health Science Center at San Antonio
-
-
Virginia
-
Lynchburg, Virginia, Spojené státy, 24501
- Lynchburg Hematology Oncology Clinic, Inc.
-
-
Washington
-
Bremerton, Washington, Spojené státy, 98310
- Harrison HealthPartners Bremerton Hematology & Oncology
-
Kirkland, Washington, Spojené státy, 98034
- Cascade Cancer Center
-
Seattle, Washington, Spojené státy, 98109
- University of Washington, Seattle Cancer Care Alliance
-
Seattle, Washington, Spojené státy, 98109
- Group Health Medical Centers
-
Spokane, Washington, Spojené státy, 99204
- Rockwood Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- University of Wisconsin, Clinical Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Histological or cytological proof of component (any percent) of clear cell RCC (renal cell carcinoma).
- Metastatic or locally advanced unresectable RCC. NOTE: Prior nephrectomy is not mandatory.
- Progressive disease after 1-2 prior VEGF-directed tyrosine kinase inhibitors (TKIs).
- Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
- Written informed consent and HIPAA authorization for release of personal health information.
- Age > 18 years at the time of consent.
- Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation.
- Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.
Exclusion Criteria:
- No active brain metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis within 30 days prior to registration on protocol therapy. NOTE: A patient with prior brain metastasis are eligible if they have completed their radiation treatment for brain metastasis ≥30 days prior to registration for protocol therapy, are off steroids, and are asymptomatic.
- No other currently active malignancy.
- No treatment with any investigational agent within 14 days prior to registration for protocol therapy. NOTE: If treated with investigational agent within 14 days prior to registration, AE must be resolved back to baseline.
- Prior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.
- Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within 30 days prior to registration for protocol therapy.
- Corrected QT interval (QTc) ≤ 450 msec at least 7 days prior to registration for protocol therapy.
- No clinically significant infections as judged by the treating investigator.
- No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
- No collecting duct, medullary or sarcomatoid histology.
- No prior treatment with temsirolimus or everolimus in the phase II component of the study. NOTE: Prior treatment with these agents is permitted in the phase I component of the study.
- No use of full dose, therapeutic anti-coagulation with warfarin or related anti-coagulants or unfractionated or low molecular weight heparins.
- No uncontrolled hypertension (BP >150/100mmHg despite full doses of 1 anti-hypertensive medication).
- No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
- No grade 2 or greater peripheral neuropathy.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Aktivní komparátor: Combination Arm A: Everolimus + BNC105P
Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
|
Everolimus 10 mg.
Taken orally, every evening, 1 hr before or 2 hrs after meals
BNC105P, up to 16 mg/m^2
|
Aktivní komparátor: Sequential Arm B:Everolimus followed by BNC105P Monotherapy
Sequential Arm B: Everolimus 10 mg, 21 day cycle Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy. |
Everolimus 10 mg.
Taken orally, every evening, 1 hr before or 2 hrs after meals
BNC105P, up to 16 mg/m^2
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus.
Časové okno: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Phase I
|
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Phase I: Toxicities of BNC105P in Combination With Everolimus.
Časové okno: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Determine the toxicities of BNC105P in combination with everolimus.
Drug-related treatment emergent adverse events by CTCAE grade 2 or greater are reported
|
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Phase II: 6-month Progression Free Survival (PFS) With the Addition of BNC105P to Everolimus.
Časové okno: 6 months
|
Improvement in 6-month PFS with the addition of BNC105P to everolimus.
Progression is defined using RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
|
6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Phase I: Response Rate of BNC105P in Combination With Everolimus.
Časové okno: Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Number of objective responses per RECIST criteria.
Complete Response (CR): Disappearance of all target lesions.
Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
|
Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months
|
Geometric Mean Half-life of BNC105 and BNC105P in Combination With Everolimus.
Časové okno: 12 months
|
Determine the PK Profile for BN105P in combination with everolimus by calculating the geometric mean half-life of BNC105P
|
12 months
|
Phase II: Response Rate With Combination Therapy Compared to Everolimus Alone
Časové okno: 12 months
|
Objective response is defined as a confirmed CR or PR per RECIST criteria.
Complete Response (CR): Disappearance of all target lesions.
Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
|
12 months
|
Phase II: Progression Free Survival (PFS) With BNC105P Alone in Patients After Progressing on Everolimus.
Časové okno: 12 months
|
Median time to progression for arm P participants who crossed over to BNC105P monotherapy after progression.
Progression is defined per RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
|
12 months
|
Phase II: Adverse Events of Everolimus and BNC105P When Administered as a Combination or Sequential Regimen.
Časové okno: 12 months
|
Determine adverse events of everolimus and BNC105P when administered as a combination or sequential regimen.
Total number of serious and non-serious adverse events for Arm A and Arm B are summarized.
Complete adverse event information is supplied in the Adverse Events reporting section.
|
12 months
|
Phase II: Overall Survival
Časové okno: 60 months
|
Determine overall survival probability, up to a maximum of 5 years from registration for protocol therapy.
|
60 months
|
Exploratory Objective: Correlation of PFS With Biomarkers
Časové okno: 6 months
|
Exploratory analysis of serum biomarkers were undertaken to generate a potential signature for response.
The correlation with 6 month progression free survival P value for four plasma biomarkers is reported.
|
6 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Thomas Hutson, D.O., Hoosier Cancer Research Network
Publikace a užitečné odkazy
Obecné publikace
- Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Theodore Logan, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Guru Sonpavde, Noah M. Hahn, Christopher Sweeney, John Sarantopoulos. Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. J Clin Oncol 30, 2012 (suppl; abstr 4603) http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=114&abstractID=91911
- John Sarantopoulos, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Jose Luis Iglesias, Guru Sonpavde, Theodore Logan, Noah M. Hahn, Christopher Sweeney, Thomas E. Hutson. A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial. J Clin Oncol 31, 2013 (suppl; abstr 4563. http://abstracts2.asco.org/AbstView_132_107981.html
- Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2015 Aug 1;21(15):3420-7. doi: 10.1158/1078-0432.CCR-14-3370. Epub 2015 Mar 18.
- Yang ES, Nassar AH, Adib E, Jegede OA, Alaiwi SA, Manna DLD, Braun DA, Zarei M, Du H, Pal SK, Naik G, Sonpavde GP. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Mol Cancer Ther. 2021 Aug;20(8):1454-1461. doi: 10.1158/1535-7163.MCT-20-1091. Epub 2021 Jun 9.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary podle histologického typu
- Novotvary
- Urologické novotvary
- Urogenitální novotvary
- Novotvary podle místa
- Onemocnění ledvin
- Urologická onemocnění
- Adenokarcinom
- Novotvary, žlázové a epiteliální
- Novotvary ledvin
- Karcinom, renální buňka
- Karcinom
- Fyziologické účinky léků
- Antineoplastická činidla
- Imunosupresivní látky
- Imunologické faktory
- Everolimus
Další identifikační čísla studie
- HOG GU09-145
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Renální buněčný karcinom
-
Northwestern UniversityNational Cancer Institute (NCI)UkončenoRakovina ledvin | Hereditary Clear Cell Renal Cell CarcinomaSpojené státy
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkStaženoRakovina ledvin | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaSpojené státy
-
Mirati Therapeutics Inc.Aktivní, ne náborClear-cell Renal Cell CarcinomaSpojené státy
-
RenJi HospitalShanghai Zhongshan Hospital; Ruijin HospitalNáborClear Cell Renal Cell Carcinoma、Rezistence na imunoterapiiČína
-
Debiopharm International SANáborDuktální adenokarcinom slinivky břišní (PDAC) | Kolorektální karcinom (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Francie, Austrálie
-
Peloton Therapeutics, Inc.Aktivní, ne náborRakovina ledvin | Renální buněčný karcinom | Rakovina ledvin | Renální buněčný karcinom (RCC) | Metastatický karcinom ledvinových buněk | Ledviny | Clear Cell Renal Cell Carcinoma (ccRCC) | Recidivující renální buněčný karcinom | Renální buněčná rakovina, recidivujícíSpojené státy
-
Regeneron PharmaceuticalsNáborMetastatický karcinom prostaty odolný proti kastraci (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)Spojené státy
-
Kura Oncology, Inc.Mirati Therapeutics Inc.NáborNemalobuněčný karcinom plic (NSCLC) | Duktální adenokarcinom slinivky břišní (PDAC) | Kolorektální karcinom (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solidní nádory se změnami HRASSpojené státy
-
Calithera Biosciences, IncUkončenoMelanom | Nemalobuněčný karcinom plic (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)Spojené státy
-
Tianjin Medical University Second HospitalZatím nenabírámeRenální buněčný karcinom | Clear Cell Renal Cell CarcinomaČína